Bromide

Bromide

SCHEMBL187607

[Br-].[Br-].[Br-].[Br-].[Br-].[K+].[K+].[K+].[K+].[K+]

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CA4 P22748 4/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL186513 1.00
Potassium Ion SCHEMBL31039834 1.00
Bromide SCHEMBL5541 1.00
Bromide SCHEMBL10505750 1.00
Bromide SCHEMBL23391655 0.82
Bromide SCHEMBL10980416 0.82 CA4 (0.67) CA4
Bromide SCHEMBL7562029 0.82 CA4 (0.67) CA4
Bromide SCHEMBL16151105 0.82
Bromide SCHEMBL11871090 0.82
Bromide SCHEMBL11821129 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1395544-B1 METHODS OF MAKING 21- 4'-(NITROOXYALKYL) BENZOATE CORTICOSTEROID DERIVATIVES AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF NICOX SA (FR) 2012-01-04 EP disclosed
EP-1395544-A4 METHODS OF MAKING 21- 4'-(NITROOXYALKYL) BENZOATE CORTICOSTEROID DERIVATIVES AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF NICOX SA (FR) 2009-05-27 EP disclosed
EP-1395544-A1 METHODS OF MAKING 21- 4'-(NITROOXYALKYL) BENZOATE] CORTICOSTEROID DERIVATIVES AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF Scynexis Chemistry and Automation, Inc. (US) 2004-03-10 EP disclosed
US-6696592-B2 FORMING REDUCED SIDE EFFECTS DERIVATIVE NICOX-S.A. (FR) 2004-02-24 US disclosed
US-20030153545-A1 Methods of making 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivatives and intermediates useful in the synthesis thereof NICOX S.A. (FR) 2003-08-14 US disclosed
WO-2002094942-A1 METHOD OF PURIFYING POLYCYCLIC DYES OPTIVA, INC. (US) 2002-11-28 WO disclosed
WO-2002094758-A1 METHODS OF MAKING 21-[4'-(NITROOXYALKYL) BENZOATE] CORTICOSTEROID DERIVATIVES AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF NICOX S. A. (FR) 2002-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153545-A1 Methods of making 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivatives and intermediates useful in the synthesis thereof CYP11B1, CYP17A1, CYP21A2 CA4 371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.